Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDBY18
|
|||
| Drug Name |
Fosgonimeton
|
|||
| Synonyms |
Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN]; UNII-H91OA9858J; H91OA9858J; 2093305-05-4; Fosgonimeton [USAN:INN]; ATH-1017; NDX-1017; WHO 11782; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; ATH-1017 FREE ACID; NDX-1017 FREE ACID; CHEMBL5095419; AKOS040757261; HY-132814; CS-0204081; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2/3 | [1] | |
| Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [2] | ||
| Company |
Athira Pharma
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C27H45N4O8P
|
|||
| Canonical SMILES |
CCCCCC(=O)NC(CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)NC(C(C)CC)C(=O)NCCCCCC(=O)N
|
|||
| InChI |
InChI=1S/C27H45N4O8P/c1-4-6-8-12-24(33)30-22(18-20-13-15-21(16-14-20)39-40(36,37)38)26(34)31-25(19(3)5-2)27(35)29-17-10-7-9-11-23(28)32/h13-16,19,22,25H,4-12,17-18H2,1-3H3,(H2,28,32)(H,29,35)(H,30,33)(H,31,34)(H2,36,37,38)/t19-,22-,25-/m0/s1
|
|||
| InChIKey |
MBYDCPOKVKDSFD-JTJYXVOQSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HGF/Met signaling pathway (HGF/Met pathway) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04886063) Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04831281) A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies. U.S.National Institutes of Health. | |||
| REF 3 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.